[Skip to Content]
[Skip to Content Landing]
Article
November 1984

Androgen Receptors and Antiandrogen Therapy for Laryngeal Carcinoma

Author Affiliations

From the Division of Otorhinolaryngology, Department of Surgery (Dr Mattox), and the Division of Oncology, Department of Medicine (Drs Von Hoff and McGuire), University of Texas Health Science Center at San Antonio, and the Otolaryngology Section, Audie Murphy Veterans Administration Hospital, San Antonio (Dr Mattox). Dr Mattox is now with Johns Hopkins Hospital, Baltimore.

Arch Otolaryngol. 1984;110(11):721-724. doi:10.1001/archotol.1984.00800370023005
Abstract

• A hydroxylapatite assay was used to assay androgen receptor levels in 23 primary laryngeal carcinomas, nine metastatic laryngeal carcinomas, and three oropharyngeal carcinomas. The median androgen receptor level in laryngeal carcinoma was 0.7 femtomoles of receptor protein per milligran of cytosol protein. Ten patients with advanced or metastatic laryngeal carcinoma and one patient with metastatic floor of mouth carcinoma were treated with the antiandrogen flutamide. There were three short-lived partial responses (1, 2, and 2.5 months) in nine patients whose tumors could be evaluated for response. Toxic reactions consisted of mild breast tenderness, and hypercalcemia in two patients with bone metastases. Androgen receptor levels did not correlate with response to flutamide. The low androgen receptor levels in laryngeal tumors may account for the relative inactivity of the antiandrogen in laryngeal cancer.

(Arch Otolaryngol 1984;110:721-724)

×